Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pimozide
Drug ID BADD_D01774
Description A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403)
Indications and Usage Used for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment.
Marketing Status Prescription
ATC Code N05AG02
DrugBank ID DB01100
KEGG ID D00560
MeSH ID D010868
PubChem ID 16362
TTD Drug ID D00KHM
NDC Product Code 66577-017; 49884-347; 76438-002; 49884-348; 14474-029
Synonyms Pimozide | Antalon | Orap | Orap forte | R-6238 | R6238
Chemical Information
Molecular Formula C28H29F2N3O
CAS Registry Number 2062-78-4
SMILES C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Seizures (incl subtypes)G protein-activated inward rectifier potassium channel 1P48549T3801210780978; 12684268; 9504382; 15150531
Sinus tachycardiaG protein-activated inward rectifier potassium channel 1P48549T3801210780978; 12684268; 9504382; 15150531
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Neuroleptic malignant syndrome12.03.01.003; 08.05.01.005; 17.05.02.003; 15.05.04.015--Not Available
Neuromyopathy17.05.03.003; 15.05.03.010--Not Available
Nocturia20.02.03.001--Not Available
Oculogyric crisis17.01.03.002; 06.05.02.002--Not Available
Opisthotonus17.01.03.005--Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Palpitations02.01.02.003--
Pancytopenia01.03.03.003--Not Available
Parkinsonism17.01.05.003--Not Available
Periorbital oedema23.04.01.002; 10.01.05.010; 06.08.03.017--
Photophobia17.17.02.006; 06.01.01.004--
Pollakiuria20.02.02.007--
Posture abnormal17.02.05.033; 15.03.01.012--Not Available
Protrusion tongue17.02.05.037; 07.14.02.002--Not Available
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Salivary hypersecretion07.06.01.009--Not Available
Schizophrenia19.03.04.001--Not Available
Sedation17.02.04.005--Not Available
Seizure17.12.03.001--
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Skin irritation23.03.04.009--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.02.05.034; 19.19.02.002; 17.02.08.003--Not Available
Syncope24.06.02.012; 02.01.02.008; 17.02.04.008--
Tachycardia02.03.02.007--Not Available
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages